178 related articles for article (PubMed ID: 21436469)
1. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
Knappskog S; Lønning PE
Oncotarget; 2011 Mar; 2(3):251-8. PubMed ID: 21436469
[TBL] [Abstract][Full Text] [Related]
2. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Knappskog S; Bjørnslett M; Myklebust LM; Huijts PE; Vreeswijk MP; Edvardsen H; Guo Y; Zhang X; Yang M; Ylisaukko-Oja SK; Alhopuro P; Arola J; Tollenaar RA; van Asperen CJ; Seynaeve C; Staalesen V; Chrisanthar R; Løkkevik E; Salvesen HB; Evans DG; Newman WG; Lin D; Aaltonen LA; Børresen-Dale AL; Tell GS; Stoltenberg C; Romundstad P; Hveem K; Lillehaug JR; Vatten L; Devilee P; Dørum A; Lønning PE
Cancer Cell; 2011 Feb; 19(2):273-82. PubMed ID: 21316605
[TBL] [Abstract][Full Text] [Related]
3. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract][Full Text] [Related]
4. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
5. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
6. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Bjørnslett M; Knappskog S; Lønning PE; Dørum A
BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
[TBL] [Abstract][Full Text] [Related]
7. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.
Knappskog S; Lønning PE
Transcription; 2011; 2(5):207-10. PubMed ID: 22231115
[TBL] [Abstract][Full Text] [Related]
8. Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).
Knappskog S; Gansmo LB; Dibirova K; Metspalu A; Cybulski C; Peterlongo P; Aaltonen L; Vatten L; Romundstad P; Hveem K; Devilee P; Evans GD; Lin D; Van Camp G; Manolopoulos VG; Osorio A; Milani L; Ozcelik T; Zalloua P; Mouzaya F; Bliznetz E; Balanovska E; Pocheshkova E; Kučinskas V; Atramentova L; Nymadawa P; Titov K; Lavryashina M; Yusupov Y; Bogdanova N; Koshel S; Zamora J; Wedge DC; Charlesworth D; Dörk T; Balanovsky O; Lønning PE
Oncotarget; 2014 Sep; 5(18):8223-34. PubMed ID: 25327560
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
[TBL] [Abstract][Full Text] [Related]
10. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
11. The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome.
Renaux-Petel M; Sesboüé R; Baert-Desurmont S; Vasseur S; Fourneaux S; Bessenay E; Frébourg T; Bougeard G
Fam Cancer; 2014 Mar; 13(1):127-30. PubMed ID: 23884452
[TBL] [Abstract][Full Text] [Related]
12. MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
Knappskog S; Gansmo LB; Romundstad P; Bjørnslett M; Trovik J; Sommerfelt-Pettersen J; Løkkevik E; ; Tollenaar RA; Seynaeve C; Devilee P; Salvesen HB; Dørum A; Hveem K; Vatten L; Lønning PE
PLoS One; 2012; 7(4):e36263. PubMed ID: 22558411
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.
Ryan BM; Calhoun KM; Pine SR; Bowman ED; Robles AI; Ambs S; Harris CC
Int J Cancer; 2012 Dec; 131(11):2710-6. PubMed ID: 22487911
[TBL] [Abstract][Full Text] [Related]
15. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
Ortiz GJ; Li Y; Post SM; Pant V; Xiong S; Larsson CA; El-Naggar AK; Johnson DG; Lozano G
Oncogene; 2018 Jan; 37(3):332-340. PubMed ID: 28925402
[TBL] [Abstract][Full Text] [Related]
16. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
18. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
Helwa R; Gansmo LB; Romundstad P; Hveem K; Vatten L; Ryan BM; Harris CC; Lønning PE; Knappskog S
Sci Rep; 2016 Sep; 6():33153. PubMed ID: 27624283
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
[TBL] [Abstract][Full Text] [Related]
20. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
